Investors in China Medical System Holdings Limited (HKG:867) had a good week, as its shares rose 8.4% to close at HK$7.23 following the release of its half-year results. It was a credible result overall, with revenues of CN¥3.6b and statutory earnings per share of CN¥0.98 both in line with analyst estimates, showing that China Medical System Holdings is executing in line with expectations. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.
Taking into account the latest results, the current consensus from China Medical System Holdings' nine analysts is for revenues of CN¥7.96b in 2024. This would reflect a decent 13% increase on its revenue over the past 12 months. Per-share earnings are expected to shoot up 25% to CN¥0.71. In the lead-up to this report, the analysts had been modelling revenues of CN¥7.94b and earnings per share (EPS) of CN¥0.72 in 2024. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.
The analysts reconfirmed their price target of HK$10.94, showing that the business is executing well and in line with expectations. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on China Medical System Holdings, with the most bullish analyst valuing it at HK$14.00 and the most bearish at HK$7.80 per share. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.
Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. The analysts are definitely expecting China Medical System Holdings' growth to accelerate, with the forecast 29% annualised growth to the end of 2024 ranking favourably alongside historical growth of 7.4% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 9.7% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that China Medical System Holdings is expected to grow much faster than its industry.
The Bottom Line
The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
With that in mind, we wouldn't be too quick to come to a conclusion on China Medical System Holdings. Long-term earnings power is much more important than next year's profits. We have forecasts for China Medical System Holdings going out to 2026, and you can see them free on our platform here.
Before you take the next step you should know about the 2 warning signs for China Medical System Holdings that we have uncovered.
Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
China Medical System Holdings Limited (HKG:867)の投資家は、半期決算発表後、株価が8.4%上昇し、HK$7.23で終値を迎え、良い週を過ごしました。売上高がCN¥36億で、法定の1株当たり利益もCN¥0.98で、どちらもアナリストの予想に沿っており、China Medical System Holdingsが期待に沿って実行していることを示しています。これは、報告書に企業のパフォーマンスを追跡でき、専門家が来年の予測を予想し、ビジネスの期待に何らかの変化があったかどうかを確認できる投資家にとって重要な時期です。そのため、最新の法定予測を集め、アナリストが来年にどのような成長を見込んでいるかを見てみました。
最新の結果を考慮した上で、China Medical System Holdingsの9人のアナリストの現在のコンセンサスは、2024年にCN¥79.6億の売上高を見込んでいます。これは過去12か月間の売上高に対して13%の増加を反映しています。1株あたりの利益は、25%増のCN¥0.71に上がる予定です。報告書の発表前、アナリストたちは2024年の売上高をCN¥79.4億、1株あたりの利益(EPS)をCN¥0.72と予測していました。コンセンサスアナリストたちは、これらの結果に何らかの大きな変化があったため、彼らのビジネスに対する見解が変化したというわけではなく、彼らの見積もりに大きな変化がないことから、ビジネスに対する見解を変更していないようです。
オーストラリアでは、moomooの投資商品及びサービスはMoomoo Securities Australia Limitedによって提供され、オーストラリア証券投資委員会(ASIC)の管理を受けております(AFSL No. 224663)。「金融サービスガイド」、「利用規約」、「プライバシーポリシー」などの詳細は、Moomoo Securities Australia Limitedのウェブサイトhttps://www.moomoo.com/auでご確認いただけます。
オーストラリアでは、moomooの投資商品及びサービスはMoomoo Securities Australia Limitedによって提供され、オーストラリア証券投資委員会(ASIC)の管理を受けております(AFSL No. 224663)。「金融サービスガイド」、「利用規約」、「プライバシーポリシー」などの詳細は、Moomoo Securities Australia Limitedのウェブサイトhttps://www.moomoo.com/auでご確認いただけます。